Lyell Immunopharma (NASDAQ:LYEL) Rating Reiterated by HC Wainwright
MarketBeatHC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Monday.
HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research report on Monday.